-
公开(公告)号：US20200009050A1
公开(公告)日：2020-01-09
申请号：US16554765
申请日：2019-08-29
申请人： NANOBIOTIX
IPC分类号： A61K9/127 , A61K31/704 , A61K9/00 , A61K9/14 , A61K9/51
摘要： The present invention relates to a pharmaceutical composition comprising the combination of (i) a biocompatible nanoparticle and of (ii) a pharmaceutical compound of interest, to be administered to a subject in need of such a compound of interest, wherein the nanoparticle potentiates the compound of interest efficiency. The longest dimension of the biocompatible nanoparticle is typically between about 4 and about 500 nm, and its absolute surface charge value is of at least 10 mV (|10 mV|). The invention also relates to such a composition for use for administering the compound of interest to a subject in need thereof, wherein the nanoparticle and the compound of interest are to be administered to said subject between more than 5 minutes and about 72 hours from each other.
-
公开(公告)号：US20160184225A1
公开(公告)日：2016-06-30
申请号：US14892271
申请日：2014-05-30
申请人： NANOBIOTIX
IPC分类号： A61K9/127 , A61K31/704
CPC分类号： A61K9/127 , A61K9/0014 , A61K9/1271 , A61K9/14 , A61K9/5115 , A61K31/704 , Y10S977/773
摘要： The present invention relates to a pharmaceutical composition comprising the combination of (i) a biocompatible nanoparticle and of (ii) a pharmaceutical compound of interest, to be administered to a subject in need of such a compound of interest, wherein the nanoparticle potentiates the compound of interest efficiency. The longest dimension of the biocompatible nanoparticle is typically between about 4 and about 500 nm, and its absolute surface charge value is of at least 10 mV (|10 mV|). The invention also relates to such a composition for use for administering the compound of interest in a subject in need thereof, wherein the nanoparticle and the compound of interest are to be administered in said subject between more than 5 minutes and about 72 hours one from each other.
摘要翻译： 本发明涉及一种药物组合物，其包含以下组合：（i）生物相容性纳米颗粒和（ii）目标药物化合物的组合，待给予需要这种感兴趣的化合物的受试者，其中所述纳米颗粒增强化合物 的利益效率。 生物相容性纳米颗粒的最长尺寸通常在约4至约500nm之间，其绝对表面电荷值至少为10mV（| 10mV |）。 本发明还涉及用于在有需要的受试者中施用感兴趣的化合物的这种组合物，其中将所述受试者中的所述纳米颗粒和所述化合物在每个所述受试者中投与大于5分钟至约72小时之间 其他。
-
公开(公告)号：US20180339062A1
公开(公告)日：2018-11-29
申请号：US16051604
申请日：2018-08-01
申请人： NANOBIOTIX
摘要： The invention pertains to a therapeutic, prophylactic or diagnostic method comprising, administering a pharmaceutical compound followed by administering a biocompatible nanoparticle comprising an oligomer of albumin, wherein the longest or largest dimension of the nanoparticle is between about 4 nm and about 500 nm. In preferred embodiments, administering the biocompatible nanoparticles is performed between more than 5 minutes and about 72 hours after administering the pharmaceutical compound. In particular embodiments, the pharmaceutical compound is a pharmaceutical antibody, such as a monoclonal antibody, a drug conjugated antibody, an engineered antibody and a multispecific antibody. According to the methods of the invention, administering the biocompatible nanoparticle comprising oligomers of albumin after administering the pharmaceutical compound maintains or increases the therapeutic benefit and reduces toxicity of the pharmaceutical compound when compared to the therapeutic benefit and toxicity induced by administering the pharmaceutical compound alone.
-
-
搜索结果
3 条记录 (耗时 0.01 秒)
